Research graph
References from Bridging the thalassaemia divide in south and southeast Asia. Local targets link to admitted publications; unresolved targets remain external evidence.
Thalassaemia
10.1016/s0140-6736(22)00536-0 · 2022 · External reference
The epidemiology of thalassaemia syndromes in southeast Asia
2026 · External reference
Thalassaemia prevention in Asia: progress, challenges, and future directions
2026 · External reference
The expanding therapeutic landscape of β-thalassaemia
2026 · External reference
Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration
2026 · External reference
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
10.1016/s0140-6736(23)00874-7 · 2023 · External reference
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(25)00635-x · 2025 · External reference
The dawn of the CRISPR/Cas9 gene therapy era
10.1016/s2352-3026(23)00372-1 · 2024 · External reference
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial
10.1016/s0140-6736(24)01884-1 · 2024 · External reference
From microscope to micropixels: a rapid review of artificial intelligence for the peripheral blood film
10.1016/j.blre.2023.101144 · 2024 · External reference
